The company had previously expected the CE mark by the end of May but several enhancements that have improved the performance of TexRAD Lung led to a delay.
Distilled to its basics, TexRAD is a very smart piece of software that analyses medical images to reveal features that are not always evident to the human eye.
This particular version of the product will help doctors diagnose and treat people with lung cancer, the most common and most deadly form of the disease.
By analysing “texture features” in CT scans, TexRAD's quantitative imaging capabilities provide clinicians with additional information to make better decisions in order to improve patient outcomes.
The award of the CE mark means Feedback can now sell TexRAD Lung to hospitals, satisfying the quality, safety and performance standards required for medical devices in the European Union.
Next step, liver cancer and COPD
"TexRAD Lung is our first TexRAD product with a CE mark which represents a significant accomplishment,” said chairman Alastair Riddell.
“This development will expedite TexRAD's clinical use in the treatment of lung cancer across the EU, expand its market presence and support the Company's ongoing commercial discussions for the technology.
"We expect that the rigorous regulatory review required for the CE mark will pave the way for TexRAD's clinical use worldwide and we are now investigating the clinical application of TexRAD in liver cancer and chronic obstructive pulmonary disease (COPD).
He added: “By arming clinicians with disease-specific tools, we believe this technology has the potential to transform radiological decision making.”